Form 8-K - Current report:
SEC Accession No. 0001493152-22-031235
Filing Date
2022-11-10
Accepted
2022-11-10 08:15:34
Documents
14
Period of Report
2022-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40686
2 ex99-1.htm EX-99.1 31908
3 ex99-1_001.jpg GRAPHIC 3646
  Complete submission text file 0001493152-22-031235.txt   256707

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE aneb-20221110.xsd EX-101.SCH 3224
5 XBRL LABEL FILE aneb-20221110_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE aneb-20221110_pre.xml EX-101.PRE 22357
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3735
Mailing Address 1415 RANCH ROAD 629 SOUTH, SUITE 201 LAKEWAY TX 78734
Business Address 1415 RANCH ROAD 629 SOUTH, SUITE 201 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

IRS No.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-40388 | Film No.: 221375069
SIC: 2834 Pharmaceutical Preparations